Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS

Alexander U. Brandt1, Hanna Zimmermann1, Falko Kaufhold1, Julia Promesberger2, Sven Schippling3, David Finis4, Orhan Aktas5, Christian Geis6, Marius Ringelstein5, E. Bernd Ringelstein7, Hans-Peter Hartung5, Friedemann Paul1,8,9, Ilka Kleffner7, Jan Dörr1,8,9

1 NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2 Department of Ophthalmology, University of Münster, Münster, Germany, 3 Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (inims), University Medical Center Hamburg Eppendorf, Hamburg, Germany, 4 Department of Ophthalmology, University Medical Center, Heinrich-Heine-University, Düsseldorf, Germany, 5 Department of Neurology, University Medical Center, Heinrich-Heine-University, Düsseldorf, Germany, 6 Department of Neurology, University of Würzburg, Würzburg, Germany, 7 Department of Neurology, University of Münster, Münster, Germany, 8 Clinical and Experimental Research Center for Multiple Sclerosis, Department of Neurology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 9 Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany

Abstract

Susac syndrome, a rare but probably underdiagnosed combination of encephalopathy, hearing loss, and visual deficits due to branch retinal artery occlusion of unknown aetiology has to be considered as differential diagnosis in various conditions. Particularly, differentiation from multiple sclerosis is often challenging since both clinical presentation and diagnostic findings may overlap. Optical coherence tomography is a powerful and easy to perform diagnostic tool to analyse the morphological integrity of retinal structures and is increasingly established to depict characteristic patterns of retinal pathology in multiple sclerosis. Against this background we hypothesised that differential patterns of retinal pathology facilitate a reliable differentiation between Susac syndrome and multiple sclerosis. In this multicenter cross-sectional observational study optical coherence tomography was performed in nine patients with a definite diagnosis of Susac syndrome. Data were compared with age-, sex-, and disease duration-matched relapsing remitting multiple sclerosis patients with and without a history of optic neuritis, and with healthy controls. Using generalised estimating equation models, Susac patients showed a significant reduction in either or both retinal nerve fibre layer thickness and total macular volume in comparison to both healthy controls and relapsing remitting multiple sclerosis patients. However, in contrast to the multiple sclerosis patients this reduction was not distributed over the entire scanning area but showed a distinct sectoral loss especially in the macular measurements. We therefore conclude that patients with Susac syndrome show distinct abnormalities in optical coherence tomography in comparison to multiple sclerosis patients. These findings recommend optical coherence tomography as a promising tool for differentiating Susac syndrome from MS.

Citation: Brandt AU, Zimmermann H, Kaufhold F, Promesberger J, Schippling S, et al. (2012) Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS. PLoS ONE 7(6): e38741. doi:10.1371/journal.pone.0038741

Editor: Markus Schuelke, Charité Universitätsmedizin Berlin, NeuroCure Clinical Research Center, Germany

Received October 26, 2011; Accepted May 9, 2012; Published June 11, 2012

Copyright: © 2012 Brandt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported in part by Deutsche Forschungsgemeinschaft (DFG Exc. 257). The MS Center at the Department of Neurology, Heinrich-Heine-University Düsseldorf, is supported in part by the Walter-and-Ilse-Rose Stiftung. The Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (inims), University Medical Center Hamburg Eppendorf, Hamburg, is supported in part by Hertie Stiftung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Susac syndrome is a rare disease characterised by the clinical triad of encephalopathy, vision disturbances, namely visual field defects, and sensorineural hearing loss [1–3]. The exact prevalence of Susac syndrome is unknown, and its pathogenesis is still unclear; autoimmune processes that lead to an occlusion of small vessels in the brain, retina and inner ear are believed to play an important role [4,5]. The disease most often manifests in the third to fourth decade [6]. The diagnosis of Susac syndrome is straightforward, when the characteristic clinical triad is complete, when the physician is familiar with the clinical presentation, and when the crucial diagnostic procedures are carried out and show characteristic findings like BRAO in FAG. However, the diagnosis is often complicated by the fact that the characteristic signs usually do not occur concomitantly but rather develop successively with symptomb-free intervals [3], which often enough results in a delayed or even completely missed diagnosis.

occlusions (BRAO), arterial wall hyperfluorescence and retinal arterial wall plaques, termed Gass plaques [10]. Retinal involvement can be missed in cases where patients do not complain about visual disturbances due to neuropsychological impairment, or when physicians are not familiar with the disease. In fact, in several reported cases BRAO was only detected after repeated FAG [6].

The diagnosis of Susac syndrome is straightforward, when the characteristic clinical triad is complete, when the physician is familiar with the clinical presentation, and when the crucial diagnostic procedures are carried out and show characteristic findings like BRAO in FAG. However, the diagnosis is often complicated by the fact that the characteristic signs usually do not occur concomitantly but rather develop successively with symptomb-free intervals [3], which often enough results in a delayed or even completely missed diagnosis. Consensus criteria for the
diagnosis of Susac syndrome have not yet been established. In MRI, Susac syndrome usually presents with “punched-out” lesions, frequently in the corpus callosum and periventricular area [11]. A number of differential diagnoses, most of which occur more frequently than Susac syndrome, have to be taken into consideration [3]. In turn, Susac syndrome should be considered as differential diagnosis in various conditions. Due to some overlap in the clinical presentation and the patterns of MRI pathology multiple sclerosis (MS) is probably the most frequent misdiagnosis of Susac syndrome [2,8,11,12]. However, with respect to the different therapeutic approach, particularly the necessity of a first-line immunosuppressive treatment in Susac syndrome in contrast to primarily immunomodulatory approaches in MS, a prompt establishment of the diagnosis is essential. Additional diagnostic criteria allowing an early differential diagnosis are therefore highly warranted.

Optical coherence tomography (OCT) has recently become a valuable addition to the neurologist’s diagnostic toolbox, proving its usefulness in a variety of disorders with neuro-ophthalmologic involvement [13–16]. OCT facilitates e.g. non-invasive quantification of both the thickness of the retinal nerve fibre layer (RNFLT), which represents unmyelinated axons of retinal ganglia converging to the optic disc to form the optic nerve and the macular volume which represents the volume of the central retina [13–16]. In a recently published case report we could demonstrate pathologic OCT findings in a patient with Susac syndrome [3]. Based on these findings we hypothesised that retinal changes (i) can be regularly detected by OCT in patients with Susac syndrome and (ii) differ from retinal pathology observed in MS. A different pattern of retinal pathology in Susac syndrome and MS would be of clinical value in terms of distinguishing patients with Susac syndrome from MS patients.

**Methods**

**Objectives**

To identify OCT changes in patients with Susac syndrome and to compare these changes with matched healthy controls and multiple sclerosis patients.

---

**Table 1.** Demographic overview of Susac patients included in the study.

| Subjects | n 9 |
|----------|----|
| Eyes     | 18 |
| Gender   | Male (%) 3 (33) Female (%) 6 (67) |
| Age (years) | Mean ± SD 33±11 |
| Time since diagnosis (months) | Mean ± SD 65±55 |
| Encephalopathy | No (%) 1 (11) |
| Hearing loss | No (%) 0 (0) |
| Visual impairment (eyes) | No (%) 3 (17) |

**Abbreviations:** BRAO = branch retinal artery occlusion; SD = standard deviation.

doi:10.1371/journal.pone.0038741.t001

**Table 2.** Optical coherence tomography data of the nine patients with Susac syndrome.

| Pat. | Sex | Age | Dur. | Eye | VS | BRAO | TMV [mm³] | A [μm] | T [μm] | S [μm] | N [μm] | I [μm] |
|------|-----|-----|------|-----|----|------|-----------|--------|--------|--------|--------|--------|
| P1   | m   | 20  | 26   | OD  | yes | yes  | 6.00      | 85     | 48     | 101    | 70     | 122    |
|      |     |     |      | OS  | yes | yes  | 7.22      | 83     | 65     | 107    | 47     | 115    |
| P2   | m   | 32  | 58   | OD  | yes | yes  | 7.64      | 105    | 81     | 132    | 106    | 102    |
|      |     |     |      | OS  | no  | yes  | 7.66      | 108    | 77     | 141    | 98     | 115    |
| P3   | f   | 44  | 173  | OD  | yes | yes  | 5.67      | 61     | 51     | 54     | 51     | 88     |
|      |     |     |      | OS  | no  | yes  | 6.11      | 61     | 49     | 64     | 53     | 77     |
| P4   | m   | 39  | 50   | OD  | yes | no   | 5.70      | 60     | 53     | 78     | 49     | 59     |
|      |     |     |      | OS  | yes | yes  | 6.63      | 82     | 63     | 95     | 60     | 111    |
| P5   | f   | 22  | 41   | OD  | yes | yes  | 6.26      | 67     | 65     | 58     | 64     | 83     |
|      |     |     |      | OS  | yes | yes  | 6.21      | 73     | 67     | 69     | 67     | 89     |
| P6   | f   | 30  | 128  | OD  | no  | no   | 6.61      | 88     | 76     | 84     | 71     | 121    |
|      |     |     |      | OS  | no  | no   | 6.64      | 93     | 70     | 125    | 64     | 115    |
| P7   | f   | 20  | 66   | OD  | yes | yes  | 6.52      | 96     | 74     | 103    | 74     | 131    |
|      |     |     |      | OS  | yes | yes  | 6.86      | 115    | 72     | 132    | 107    | 149    |
| P8   | f   | 45  | 69   | OD  | yes | yes  | 5.25      | 62     | 52     | 70     | 41     | 83     |
|      |     |     |      | OS  | yes | yes  | 5.55      | 52     | 57     | 56     | 31     | 65     |
| P9   | f   | 47  | 3    | OD  | yes | yes  | 6.66      | 86     | 74     | 103    | 63     | 103    |
|      |     |     |      | OS  | yes | yes  | 6.57      | 79     | 69     | 99     | 56     | 93     |

**Abbreviations:** Pat. = Patient No; Age = age of onset; Dur. = time since diagnosis at time of OCT measurement in months; OD = right eye; OS = left eye; VS = visual symptoms; BRAO = branch retinal artery occlusion; TMV = total macular volume in mm³; A = average retinal nerve fibre layer thickness (RNFLT) in μm; T = temporal, S = superior, N = nasal, I = inferior quadrant’s RNFLT in μm.

doi:10.1371/journal.pone.0038741.t002
Study Design and Participants
This is a prospective, cross-sectional, multicentre observational study documenting OCT findings in Susac syndrome patients. Patients with definite diagnosis of Susac syndrome, aged ≥18 years were recruited from the neurologic outpatient clinics of five large university medical centres (Berlin, Münster, Düsseldorf, Hamburg, and Würzburg, Germany). Exclusion criteria were inability to provide informed consent. All included patients underwent complete neurological examination. Medical history, particularly with respect to encephalopathy, visual symptoms, and hearing loss was taken from all study participants. In cases where the classical clinical triad was not present, diagnosis was established on clinical presentation and MRI findings. Visual testing was performed with bedside visual field testing. Age and gender matched healthy controls (HC) and patients with relapsing remitting MS (RRMS) were randomly selected from the imaging research database of the NeuroCure Clinical Research Center (NCRC) at Charité – Universitätsmedizin Berlin by an investigator blinded to the OCT data.

Ethics
The study was approved by the local ethics committees and was conducted in accordance to the Declaration of Helsinki in its currently applicable version, the guidelines of the International Conference on Harmonisation of Good Clinical Practice (ICH-GCP), and the applicable German laws. All participants gave informed written consent.

Optical Coherence Tomography
RNFLT and TMV were measured with Stratus 3000 OCT (Carl Zeiss Meditec, California, USA) using “Fast RNFL 3.4” and “Fast Macula Thickness Map” protocols (software V4.0) by trained personnel. For RNFLT, a 3.4 mm diameter circular scan was acquired circumferentially to the optic disc, and for TMV six radial lines were taken, centred within the fovea. A good quality image was defined as having generalised signal distribution, a reflectance signal from either RNFL or retinal pigment epithelium strong enough to identify either layer, no missing parts caused by eye movements, and a signal strength of ≥7 of 10 [17]. Segmentation lines for upper and lower borders of RNFL were required to be on the internal limiting membrane and lower border of the RNFL. For the comparison of OCT measurements to normative data, the device’s internal normative database, comprising of measurements of 170 eyes from HC was used as a reference. Percentile positions of measurements compared to these normative data are automatically given on the device’s TMV and RNFLT report as below 1 st percentile, between 1 st and 5 th percentile, between 5 th and 95 th percentile, and above 95 th percentile.

Statistical methods
Differences in age and time since diagnosis between patients with Susac syndrome, HC and RRMS patients with and without a history of optic neuritis were analysed using Friedman’s analysis for matched pairs. Differences between eyes from the groups were assessed using generalised estimating equation models (GEE) accounting for intra-patient/inter-eye dependencies. To further rule out possible age related effects or effects related to minor differences in time since diagnosis, GEE models were corrected for age and additionally with time since diagnosis for comparisons against RRMS patients. In all GEE, the diagnostic group was used as independent categorical variable. Mean values in text are given with standard deviation (SD) after a ± sign. All statistical tests were performed using SPSS 20 (IBM, Somers, NY, USA). For all calculations, statistical significance was established at p<0.05.

Results
Cohort description
Nine patients with Susac syndrome were prospectively recruited (six jointly from Berlin and Münster, one from each of the other

Table 3. Mean values from optical coherence tomography measurements of the macula (total macular volume and below) and the circular scan around the optic nerve head (RNFLT Average and below).

|                      | Susac Mean (SD Min Max) | HC Mean (SD Min Max) | MS-NON Mean (SD Min Max) | MS-ON Mean (SD Min Max) |
|----------------------|-------------------------|----------------------|--------------------------|-------------------------|
| Total Macular Volume | 6.43 (0.67 5.25 7.66)   | 7.14 (0.35 6.65 7.09) | 6.51 (0.36 6.51 7.75)    | 6.73 (0.49 6.04 7.68)   |
| Inner Macula T [µm]  | 240 (33 172 284)        | 269 (18 238 296)     | 254 (18 254 311)         | 254 (14 258 301)        |
| S [µm]               | 242 (55 128 300)        | 283 (16 255 308)     | 280 (18 254 311)         | 280 (11 258 305)        |
| N [µm]               | 271 (26 207 306)        | 282 (17 256 312)     | 280 (18 254 311)         | 280 (11 258 305)        |
| I [µm]               | 254 (42 146 301)        | 280 (18 254 311)     | 280 (18 254 311)         | 280 (11 258 305)        |
| Outer Macula T [µm]  | 205 (27 160 243)        | 229 (11 213 252)     | 211 (11 211 251)         | 219 (18 193 252)        |
| S [µm]               | 209 (42 139 263)        | 247 (12 231 276)     | 245 (14 222 266)         | 234 (17 209 263)        |
| N [µm]               | 246 (18 211 267)        | 264 (14 248 291)     | 262 (16 232 291)         | 248 (18 214 281)        |
| I [µm]               | 222 (30 143 265)        | 242 (12 223 262)     | 241 (11 216 267)         | 226 (18 200 266)        |
| RNFLT Average [µm]   | 81 (18 52 115)          | 107 (9 91 120)       | 102 (14 87 137)          | 95 (11 74 118)          |
| RNFLT T [µm]         | 65 (11 48 81)           | 75 (12 59 101)       | 73 (17 49 109)           | 77 (14 29 57)           |
| S [µm]               | 93 (28 54 141)          | 133 (14 104 158)     | 123 (17 104 164)         | 150 (16 87 113)         |
| N [µm]               | 65 (21 31 107)          | 85 (16 67 120)       | 82 (21 47 142)           | 123 (16 62 90)          |
| I [µm]               | 101 (24 59 149)         | 132 (14 109 150)     | 128 (17 105 163)         | 139 (16 89 120)         |

Abbreviations: RRMS = relapsing-remitting multiple sclerosis; HC = healthy controls; SD = standard deviation; RNFLT = retinal nerve fibre layer thickness; t = temporal; S = superior; N = nasal; l = inferior.

doi:10.1371/journal.pone.0038741.t003
Figure 1. Macular and ring scans from patients with Susac syndrome and matched RRMS patients. Shown are only the left eyes (randomly selected to save space) from each Susac patient (P1-9) and the corresponding left eyes from RRMS patients without history of optic neuritis (MS-NON) and RRMS patients with history of optic neuritis (MS-ON). On the bottom, a comparison of scans from one of the healthy controls is given. A) Colour coded is the calculated macular thickness from the device’s segmentation algorithm with black to blue for reduced thickness and yellow to green for normal thickness (left legend on the bottom). The macular thickness map is calculated from six linear scans through the centre of the macula. Of note is the different distribution of the damage. B) For RNFLT scans, the thickness from 12 clock-hour segments of the circular scan is given. Colour coded is the thickness relative to the normative database with green and white meaning normal values above the 95th or 95th percentile and yellow and red meaning reduction of thickness below the 5th or 10th percentile (right legend on the bottom). Whereas some Susac patients’ eyes show striking sectoral damage, eyes from RRMS patients show an even thinning with an accentuation in the outer temporal areas, that is further pronounced with a history of optic neuritis. Three Susac patients (P6, 7, 9) show a similar pattern.

DOI:10.1371/journal.pone.0038741.g001

three centres). A demographic overview is given in table 1, and a multiple case presentation is provided in table 2. The female to male ratio of 2:1 reflected that reported in the literature. All patients had a history of hearing loss, and all but one patient (P2) had symptoms of encephalopathy. All patients except one (P6) had a history of visual symptoms and provided accompanying reports of BRAO. Additionally, one patient (P2) had visual symptoms on the right eye. However, in this patient a report of BRAO did exist for both eyes. At the time of OCT investigation, no patient was in a clinically active phase of the disease.

Macular and retinal nerve fibre layer damage

Single case OCT measurements are given in table 2, and a synopsis is provided in table 3. In summary, compared to the normative database of the OCT device, most patients showed a reduction in either average RNFLT or macular measurements. All but one patient (P2) with a history of visual symptoms showed either reduced average RNFLT and/or diminished TMV in at least one eye. P2 showed a very mild clinical phenotype and TMV was above the 95th percentile when compared to the normative database of the device. Interestingly, one patient without visual symptoms and without documented BRAO (P6) did also present a pathological OCT with a strong RNFLT reduction in the superior quadrant of the right eye, although average RNFLT in this eye was normal (figures 1 and 2).

Importantly, TMV and RNFLT reduction were not evenly distributed over the entire scanning area but scattered over all sectors (figure 1 and figure 2). Patients with Susac syndrome showed a RNFLT below the 5th percentile in a mean 3.6±2.3 (range 0–10) of the twelve clock-hour sectors and a TMV below the 5th percentile in a mean 2.4±2.9 (range 0–7) of the nine macular sectors whereas the other sectors were within normal ranges. All but one patient (P2) showed this patchy retinal damage in at least one eye as indicated by the yellow and red areas in the RNFLT measurements and the dark blue areas in the TMV measurements (figure 1).

Comparison to matched healthy controls and multiple sclerosis patients

To compare OCT results from patients with Susac syndrome to results from HC and RRMS patients, either group of nine gender and age matched HC (mean age 33±11 years, 3/6 male/female), nine RRMS patients without any history of optic neuritis (mean age 32±10 years, 3/6 male/female, time since diagnosis 55±20 months) and nine RRMS patient with a previous bilateral optic neuritis (mean age 33±9 years, 3/6 male female, time since diagnosis 38±24 months) was considered. HC and RRMS patients were matched for gender, age and time since diagnosis. Gender was matched exactly 1:1. The differences in age were not significant (Friedman’s analysis for matched pairs p = 0.061). Likewise, time since diagnosis of RRMS patients with and without previous optic neuritis was statistically not different from Susac patients (Friedman’s analysis for matched pairs p = 0.062).

Average RNFLT was reduced in patients with Susac syndrome (average RNFLT 81±18 μm, table 3) in comparison to HC (average RNFLT 107±9 μm, coefficient B = -25.5, SE 6.2, p<0.001, GEE), RRMS patients without previous optic neuritis (average RNFLT 102±14 μm, coefficient B = -21.3, SE 6.2, p = 0.001, GEE) and RRMS patients with a history of optic neuritis (average RNFLT 95±11 μm, coefficient B = -13.5, SE 5.8, p = 0.019, GEE) (figure 1B, 2 and 3). Accordingly, TMV was reduced in patients with Susac syndrome (TMV 6.4±0.67 mm³, table 3) in comparison to HC (TMV 7.14±0.35 mm³, coefficient B = -0.71, SE 0.22, p = 0.001, GEE), RRMS patients without history of optic neuritis (TMV 7.09±0.36 mm³, coefficient B = -0.67, SE 0.20, p = 0.001, GEE) but not against RRMS patients with previous history of optic neuritis (TMV 6.73±0.49 mm³, coefficient B = -0.23, SE 0.21, p = 0.224, GEE) (figure 1 and 3).

Discussion

In this cross-sectional, observational study we investigated nine patients with Susac syndrome using OCT and compared RNFLT and TMV data with nine gender and age matched HC and nine RRMS patients each with or without history of optic neuritis. Our main findings are (a) pathologic OCT measurements in most of the Susac patients with a history of visual symptoms when compared to the normative database of the OCT device; (b) reduced RNFLT and macular measurements when compared to gender and age matched HC; (c) a more severe retinal nerve fibre damage in patients with Susac syndrome as compared to RRMS patients irrespective the history of optic neuritis despite a similar disease duration, and most importantly (d) distinct patterns of retinal or retinal nerve fibre layer damage among patients with Susac syndrome compared to RRMS patients that can help to discriminate between both diseases. Although a rare disease, Susac syndrome needs to be considered in the differential diagnosis of a variety of neurological disorders. Currently, its diagnosis is based primarily on the clinical presentation, the documentation of BRAO by FAG, and characteristic findings on cranial magnetic resonance imaging, including subtle changes such as fibre impairment detected by diffusion tensor imaging [18]. Recently, anti-endothelial antibodies in Susac syndrome were reported as a potential future diagnostic criterion and as a possible pathologic correlate [19,20].

The majority of patients with Susac syndrome in this study showed a characteristic and thus very distinct pattern of often severe and patchy retinal nerve fibre thinning in RNFLT and retinal damage in TMV. Compatible with the pathology of this retinal microangiopathy, retinal damage was usually scattered over distinct foci and not evenly distributed: whereas several sectors in RNFLT and/or TMV showed severe damage, other sectors remained completely normal. The notable exclusion from that rule was patient P2, who had a mostly normal RNFLT and TMV, despite visual symptoms and BRAO findings in FAG.
This presentation of Susac syndrome in OCT is in contrast to OCT findings in MS. Several publications that were recently reviewed in a meta-analysis [16], report an evenly distributed thinning of RNFL in MS that is slightly enhanced on the temporal quadrant after optic neuritis [21]. However, RNFL thinning in MS accumulates over time and becomes more severe especially in later stages of the disease. In early stages of MS and in clinically isolated syndrome (CIS), when differentiation of Susac syndrome is most important, RNFL thinning is barely detectable [22]. However, since Susac patients in this study’s cohort had an
established diagnosis already for several months or even years, it is not clear, how early Susac syndrome with acute visual impairment and BRAO translate into pathological OCT findings.

The crucial question in this context is at what time point OCT starts to show abnormal findings in patients with Susac syndrome. A few case reports and one study with nine BRAO patients without underlying Susac syndrome report an initial thickening of RNFL leading to final thinning after several months [23–25]. In general, one would suspect that structural retinal nerve fibre damage evolves some time after the underlying vessel pathology. One patient (P6) however showed an abnormal OCT even without BRAO in FAG pointing towards a potential usability of OCT in earlier stages of the disease when the diagnosis is yet not fully established. This issue should be addressed in a longitudinal study investigating the development of retinal lesions of newly diagnosed patients with Susac syndrome and BRAO over time including functional visual outcomes. Due to the design of our study, it was not possible to perform FAG and OCT at the same time, unfortunately limiting the possibility to make assertions on the co-occurrence of OCT and BRAO findings in this respect. Therefore, these questions are currently investigated in a follow up study.

Beyond differential diagnosis, the severe structural retinal damage in Susac syndrome especially in the macular scans detected by OCT supports an aggressive treatment regimen early after diagnosis [8]. This notion is further assisted by the fact that patient (P6) without visual symptoms showed a pathological OCT, suggesting early subclinical retinal damage. On the other hand, one patient (P2) with actual BRAO did not have pathological findings in OCT. Thus, BRAO does not always lead to pathological OCT findings. The dissociation of retinal damage and history of BRAO observed in P2 and P6 might suggest additional mechanisms independent of BRAO underlying retinal damage in this disease.

The reported study has important limitations that need to be considered. Due to the rarity of the disease, recruitment of a sufficient number of patients is challenging and prospective data on Susac syndrome derived from studies with more than five patients hardly exist. Although data on a limited number of nine patients obviously need to be interpreted cautiously, our study is among the largest prospective studies so far reported on Susac syndrome [26–28]. However, conclusions on the discriminatory ability of OCT between Susac syndrome and MS should be interpreted with care from this study with only small numbers.

Another important limitation of our study is the use of a time domain OCT device that measures macular volume using a six-line scan protocol instead of a volume/3D scan. A thickness map is generated via interpolating the measurements between the six line scans. The distinct and striking sectoral damage in the macular scans might therefore be under- or overestimated. Since the macular scan incorporates all retinal layers between the inner limiting membrane and the retinal pigment epithelium, it is not possible to determine via time domain OCT alone, which retinal layers are affected in Susac syndrome in comparison to optic neuritis. Because of the vascular nature of the disease, one might speculate though, that any damage would be more profound and affecting more retinal layers when compared to optic neuritis. Furthermore, the used time domain OCT device has known limitations in the reproducibility of sectoral RNFLT [29]. Next generation spectral domain OCT devices provide volume 3D scans and intra-retinal segmentation algorithms [30], possibly further enhancing the value of OCT in the differential diagnosis of Susac syndrome. However, in contrast to spectral domain OCT, time domain OCT is already widely available and patients with Susac syndrome show the reported distinct phenotype in time domain OCT [26–28]. However, conclusions on the discriminatory ability of OCT between Susac syndrome and MS should be interpreted with care from this study with only small numbers.

In summary, we show that Susac patients regularly have distinct abnormalities in OCT scans. The sectorial pattern of retinal damage supports the hypothesis of a vascular origin with patchy lesions. Most importantly, our data recommends OCT as a tool in early primary and secondary diagnostics of Susac syndrome when differentiation from MS and other neuroimmunologic diseases can prove challenging.

Acknowledgments

We thank our study nurses Franziska Lipske and Katja Wolf for important logistical support.
Author Contributions
Conceived and designed the experiments: JD IK FP AUB. Performed the experiments: HZ FK JP SS DF OA CG IK JD. Analyzed the data: JD AUB FP. Wrote the paper: AUB IK JD. Provided important intellectual input into design and conduct of study: OA EBR HPH FP. Provided crucial logistic support: EBR CG OA MR HPH. Critically revised the manuscript for intellectual content: HZ FK JP SS DF OA CG MR EBR HPH FP.

References
1. Susac JO, Hardman JM, Selhorst JB (1979) Microangiopathy of the brain and retina. Neurology 29: 313–316.
2. Susac JO (1994) Susac’s syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology 44: 591–593.
3. Dorr J, Radbruch H, Bock M, Wuerfel J, Bruggemann A, et al. (2009) Encephalopathy, visual disturbance and hearing loss—recognizing the symptoms of Susac syndrome. Nat Rev Neurol 5: 653–660.
4. Petty GW, Engel AG, Young SR, Duffy J, Yanagihara T, et al. (1998) Retinocochleocerebral vasculopathy. Medicine (Baltimore) 77: 12–40.
5. McLeod DS, Ying HS, McLeod CA, Grebe R, Lubow M, et al. (2011) Retinal and optic nerve head pathology in Susac’s syndrome. Ophthalmology 118: 548–552.
6. Susac JO, Egan RA, Rennebohm RM, Lubow M (2007) Susac’s syndrome: 1973–2005 microangiopathy/autoimmune endotheliopathy. J Neurol Sci 257: 270–272.
7. Petty GW, Matteson EL, Younge BR, McDonald TJ, Wood CP (2001) Recurrence of Susac syndrome (retinocochleocerebral vasculopathy) after remission of 18 years. Mayo Clin Proc 76: 958–960.
8. Rennebohm RM, Egan RA, Susac JO (2006) Treatment of Susac’s Syndrome. Curr Treat Options Neurol 10: 67–74.
9. Rennebohm RM, Susac JO (2007) Treatment of Susac’s syndrome. J Neurol Sci 257: 215–220.
10. Egan RA, Hills WL, Susac JO (2010) Gass plaques and fluorescein leakage in Susac Syndrome. J Neurol Sci 299: 97–100.
11. Rennebohm R, Susac JO, Egan RA, Daroff RB (2010) Susac’s Syndrome – update. J Neurol Sci 299: 86–91.
12. O’Halloran HS, Pearson PA, Lee WB, Susac JO, Berger JR (1998) Microangiopathy of the brain, retina, and cochlea (Susac syndrome): A report of five cases and a review of the literature. Ophthalmology 105: 1038–1044.
13. Frohman EM, Costello F, Zivadinov R, Stuve O, Conger A, et al. (2006) Optical coherence tomography in multiple sclerosis. Lancet Neurol 5: 853–863.
14. Frohman EM, Fujimoto JT, Frohman TC, Calabresi PA, Cutter G, et al. (2008) Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nature Clinical Practice Neurology 4: 664–675.
15. Naimith RT, Toflah NT, Noz C, Kläwer EC, Shepherd J, et al. (2009) Optical coherence tomography differs in neuroaxonal dystrophy compared with multiple sclerosis. Neurology 72: 1077–1082.
16. Petzold A, de Boer JF, Schippling S, Vemtersch P, Kardon R, et al. (2010) Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 9: 921–932.
17. Cheung CYL, Leung CKS, Lin D, Pang C-P, Lam DSC (2008) Relationship between retinal nerve fiber layer measurement and signal strength in optical coherence tomography. Ophthalmology 115: 1347–51, 1351.e1–2.
18. Kleffner I, Deppe M, Mohammadi S, Schwindt W, Stepp N, et al. (2008) Diffusion tensor imaging demonstrates fiber impairment in Susac syndrome. Neurology 70: 1867–1869.
19. Jarius S, Neumayer B, Wandinger KP, Hartmann M, Wildehmann B (2009) Anti-endothelial serum antibodies in a patient with Susac’s syndrome. J Neurol Sci 285: 259–261.
20. Magro CM, Poe JC, Lubow M, Susac JO (2011) Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am J Clin Pathol 136: 905–912.
21. Bock M, Brandt AU, Dörj J, Kraft H, Wemge-Evers N, et al. (2010) Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg 112: 647–652.
22. Outteryck O, Zephir H, Defoort S, Bouyon M, Debruyne P, et al. (2009) Optical coherence tomography in clinically isolated syndrome: no evidence of subclinical retinal axonal loss. Arch Neurol 66: 1373–1377.
23. Asefzadeh B, Ninoy K (2008) Longitudinal analysis of retinal changes after branch retinal artery occlusion using optical coherence tomography. Ophthalmology 79: 85–89.
24. Takahasi H, Iijima H (2009) Sectoral thinning of the retina after branch retinal artery occlusion. Jpn J Ophthalmol 53: 494–500.
25. Shah VA, Wallace B, Sabates NR (2010) Spectral domain optical coherence tomography findings of acute branch retinal artery occlusion from calcific embolus. Indian J Ophthalmol 58: 523–524.
26. Susac JO, Murtagh FR, Egan RA, Berger JR, Bakshi R, et al. (2003) MRI findings in Susac’s syndrome. Neurology 61: 1783–1787.
27. Aubart-Cohen F, Klein I, Alexandra J-F, Bodaghi B, Doan S, et al. (2007) Long-term outcome in Susac syndrome. Medicine (Baltimore) 86: 93–102.
28. Kleffner I, Deppe M, Mohammadi S, Schwindt W, Sommer J, et al. (2010) Neuroimaging in Susac’s syndrome: focus on DTI. J Neurol Sci 299: 92–96.
29. Cettomai D, Pulicken M, Gordon-Lipkin E, Salter A, Frohman TC, et al. (2008) Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol 65: 1218–1222.
30. Saidha S, Syc SB, Ibrahim MA, Eckstein C, Warner CV, et al. (2011) Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 134: 518–533.